Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Amortization of Goodwill: 2024-2025

  • Maravai Lifesciences Holdings' Amortization of Goodwill was N/A to $30.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $363.3 million, marking a year-over-year change of. This contributed to the annual value of $166.2 million for FY2024, which is N/A change from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Amortization of Goodwill stood at $30.4 million for Q2 2025, which was up 144.87% from $12.4 million recorded in Q1 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Amortization of Goodwill peaked at $166.2 million during Q4 2024, and registered a low of $12.4 million during Q1 2025.
  • Its 2-year average for Amortization of Goodwill is $90.8 million, with a median of $92.3 million in 2024.